luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
Published 1 year ago • 182 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
1:01
choosing the correct parp inhibitor for prostate cancer
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
0:23
future studies for the combination of 177lu-psma-617 and olaparib
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
1:21
combining a parp and pd-l1 inhibitor to treat prostate cancer
-
2:48
assessing parp inhibition and brca1/2 as a prognostic biomarker in mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
4:48
vision: lu-177-psma-617 in mcrpc
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
2:04
phase i/ii trial of 177lu−j591 and 177lu−psma−617 in mcrcp
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer